Aptullahoglu, E.; Howladar, M.; Wallis, J.P.; Marr, H.; Marshall, S.; Irving, J.; Willmore, E.; Lunec, J.
Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia. Cancers 2025, 17, 274.
https://doi.org/10.3390/cancers17020274
AMA Style
Aptullahoglu E, Howladar M, Wallis JP, Marr H, Marshall S, Irving J, Willmore E, Lunec J.
Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia. Cancers. 2025; 17(2):274.
https://doi.org/10.3390/cancers17020274
Chicago/Turabian Style
Aptullahoglu, Erhan, Mohammed Howladar, Jonathan P. Wallis, Helen Marr, Scott Marshall, Julie Irving, Elaine Willmore, and John Lunec.
2025. "Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia" Cancers 17, no. 2: 274.
https://doi.org/10.3390/cancers17020274
APA Style
Aptullahoglu, E., Howladar, M., Wallis, J. P., Marr, H., Marshall, S., Irving, J., Willmore, E., & Lunec, J.
(2025). Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia. Cancers, 17(2), 274.
https://doi.org/10.3390/cancers17020274
